Probiotic supplementation reduces systemic inflammation in dialysis patients

Probiotic supplementation reduces systemic inflammation in dialysis patients: the effect on circulating regulatory T-cells and pro-inflammatory monocytes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005417

Enrollment

Registered

2020-09-23

Start date

2018-12-12

Completion date

Unknown

Last updated

2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Supplementation of probiotics for 3 months with other medications maintained probiotics : Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Enrolled patients included those aged > 18 years undergoing maintenance dialysis for more than 3 months

Exclusion criteria

Exclusion criteria: patients who were a) were on HD for acute kidney injury; (b) were on HD less than twice per week; (c) had uncontrolled diarrhea or gastrointestinal infection; (d) were treated with oral or intravenous antibiotics within 4 weeks of enrollment; and (e) were actively being treated for cancer, or with immunosuppressive drugs.

Design outcomes

Primary

Measure	Time frame
% Tregs, number of proinflammatory monocytes in blood	—

Secondary

Measure	Time frame
Iinflammatory cytokines, fecal short chain fatty acids	—

Countries

Korea, Republic of

Contacts

Public ContactSang Kyung Jo

Korea University Anam Hospital

Outcome results